Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 45, Issue 10, 2004, Pages 2017-2027

  Johnston, James B ^a,b   Paul, James T ^a   Neufeld, Nathan J ^a   Haney, Neil ^a   Kropp, Dianne M ^a   Hu, Xiaojie ^a   Cheang, Mary ^b   Gibson, Spencer B ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Chronic lymphocytic leukemia; Clinical staging; Drug resistance; Mcl 1

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CELL PROTEIN; CHLORAMBUCIL; FLUDARABINE; MYELOID CELL FACTOR 1; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER STAGING; CANCER SURVIVAL; CELL ASSAY; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEUKEMIA CELL; LYMPHOCYTE COUNT; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STATISTICAL ANALYSIS; T LYMPHOCYTE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; CELL SURVIVAL; CELLS, CULTURED; CHLORAMBUCIL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-BCL-2; VIDARABINE;

EID: 4544348358     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190410001723317     Document Type: Article

References (53)

1. Johnston, J.B. (1999) Chronic lymphocytic leukemia. In Wintrobe's Clinical Hematology, 10th Edition, edited by G.R. Lee, J. Foerster, J. Lukens, F. Paraskevas, G.R. Greer and G. M. Rodgers. Pp 2405-2427. Baltimore, MD: Williams and Wilkins.
2. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S., et al. (1996) "National Cancer Institute - sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment", Blood, 87, 4990-4997.
3. Caligaris-Cappio, F. and Hamblin, T.J. (1999) "B-cell chronic lymphocytic leukemia: a bird of a different feather", Journal of Clinical Oncology, 17, 399-408.
4. Rosenwald, A., Alizadeh, A.A., Widhopf, G., Simon, R., Davis, R.E., Yu, X., et al. (2001) "Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia", Journal of Experimental Medicine, 194, 1639-1646.
5. Oscier, D.G., Gardiner, A.C., Mould, S.J., Glide, S., Davis, Z.A., Ibbotson, R.E., et al. (2002) "Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors", Blood, 100, 1177-1184.
6. H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia", Blood, 100, 1410-1416.
7. Rai, J.L., Sawitsky, A., Cronkite, E.P., Chanana, A.D., Levy, R.N. and Pasternack, B.S. (1975) "Clinical staging of chronic lymphocytic leukemia", Blood, 46, 219-234.
8. Molica, S. and Alberti, A. (1987) "Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia", Cancer, 60, 2712-2716.
9. Dighiero, G. and Binet, J-L. (2000) "When and how to treat chronic lymphocytic leukemia", New England Journal of Medicine, 343, 1799-1801.
10. Rai, K.R., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., et al. (2000) "Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia", New England Journal of Medicine, 343, 1750-1757.
11. Leporrier, M., Chevret, S., Cazin, B., Boudjerra, N., Feugier, P., Desablens, B., et al. for the French Cooperative Group on Chronic Lymphocytic Leukemia. (2001) "Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients", Blood, 98, 2319-2325.
12. Hanada, M., Delia, D., Aiello, A., Stadtmauer, E. and Reed, J.C. (1993) "Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia", Blood, 82, 1820-1828.
13. Robertson, L.E., Plunkett, W., McConnell, K., Keating, M.J. and McDonnell, T.J. (1996) "Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome", Leukemia, 10, 456-459.
14. Christodoulopoulos, G., Fotouhi, N., Krajewski, S., Reed, J.C., Alaoui-Jamali, M. and Panasci, L. (1997) "Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of Bcl-2, Bax, Bcl-X and p53", Cancer Letters, 121, 59-67.
15. Johnston, J.B., Daeninck, P., Verburg, L., Lee, K., Williams, G., Israels, L.G., et al. (1997) "p53, mdmd-2, bax and bcl-2 and drug resistance in chronic lymphocytic leukemia", Leukemia and Lymphoma, 26, 435-449.
16. Pepper, C., Hoy, T. and Bentley, P. (1998) "Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic leukaemia and are correlated with in vivo chemoresistance", Leukemia and Lymphoma, 28, 355-361.
17. Kitada, S., Anderson, J., Akar, S., Zapata, J.M., Takayama, S., Krajewski, S., et al. (1998) "Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses", Blood, 91, 3379-3389.
18. Pepper, C., Thomas, A., Hoy, T., Cotter, F. and Bentley, P. (1999) "Antisense-mediated suppression of bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia", British Journal of Haematology, 107, 611-615.
19. Hentgartner, M.O. (2000) "The biochemistry of apoptosis", Nature, 407, 770-776.
20. Kroemer, G. (1997) "The proto-oncogene Bcl-2 and its role in regulating apoptosis", Nature Medicine, 3, 614-620.
21. Craig, R.W. (2002) "MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentation and tumorigenesis", Leukemia, 16, 444-454.
22. Zhang, D., Li, F., Weidner, D., Mnjoyan, Z.H. and Fujise, K. (2002) "Physical and functional interaction between myeloid cell leukemia 1 protein (MCL1) and fortilin. The potential role of Mcl1 as a fortilin chaperone", Journal of Biological Chemistry, 277, 37430-37438.
23. Zhang, B., Gojo, I. and Fenton, R.G. (2002) "Myeloid cell factor-1 is a critical survival factor for multiple myeloma", Blood, 99, 1885-1893.
24. L is an essential survival protein of human myeloma cells", Blood, 100, 194-199.
25. Moulding, D.A., Giles, R.V., Spiller, D.G., White, M.R.H., Tidd, D.M. and Edwards, S.W. (2000) "Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells", Blood, 96, 1756-1763.
26. Fujise, K., Zhang, D., Liu, J-I. and Yeh, E.T.H. (2000) "Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen", Journal of Biological Chemistry, 275, 39458-39465.
27. Kozopas, K.M., Yang, T., Buchan, H.L., Zhou, P. and Craig, R.W. (1993) "MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2", Proceedings of the National Academy USA, 90, 3516-3520.
28. Yang, T., Kozopas, K.M. and Craig, R.W. (1995) "The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2", Journal of Cellular Biology, 128, 1173-1184.
29. Yang, T., Buchan, H.L., Townsend, K.J. and Craig, R.W.J. (1996) "MCL-1, a member of the BCL-2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation", Journal of Cellular Physiology, 166, 523-536.
30. Zhou, P., Levy, N.B., Xie, H., Qian. L., Lee, C.Y., Gascoyne, R.D., et al. (2001) "MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes" , Blood, 97, 3902-3909.
31. Opferman, J.T., Letai, A., Beard, C., Sorcinelli, M.D., Ong, C.C. and Korsmeyer, S.J. (2003) "Development and maintenance of B and T lymphocytes require antiapoptotic MCL-1", Nature, 426, 671-676.
32. Pedersen, I.M., Kitada, S., Leoni, L.M., Zapata, J.M., Karras, J.G., Tsukada, N., et al. (2002) "Protection of CLL B cells by a follicular dendritic cell line dependent on induction of Mcl-1" , Blood, 100, 1795-1801.
33. Bellosillo, B., Villamor, N., Colomer, D., Pons, G., Montserrat, E. and Gil, J. (1999) "In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia", Blood, 94, 2836-2843.
34. Pérez-Galán, P., Marzo, I., Giraldo, P., Rubio-Félix, D., Lasierra, P., Larrad, L., et al. (2002) " Role of caspases and apoptosis-inducing factor (AIF) in cladribine-induced apoptosis of B cell chronic lymphocytic leukemia", Leukemia, 16, 2106-2114.
35. Kitada, S., Zapata, J.M. Andreeff, M. and Reed, J.C. (2000) "Protein kinase inhibitors flavopiridol and 7-hydroy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia", Blood, 96, 393-397.
36. Pepper, C., Thomas, A., Hoy, T., Fegan, C. and Bentley, P. (2001) "Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia", British Journal of Haematology, 114, 70-77.
37. Begleiter, A., Verburg, L., Ashique, A., Lee, K., Israels, L.G., Mowat, M.R.A., et al. (1995) "Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-β -arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro", Leukemia, 9, 1875-1881.
38. Levesque, M.C., O'Loughlin, C.W. and Weinberg, J.B. (2001) "Use of serum-free media to minimize apoptosis of chronic lymphocytic leukemia cells during in vitro culture", Leukemia, 15, 1305-1307.
39. Gibson, E.M., Henson, E.S., Haney, N., Villanueva, J. and Gibson, S.B. (2002) "Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis by inhibiting cytochrome c release", Cancer Research, 62, 488-496.
40. Van Stijn, A., van der Pol, M.A., Feller, N., Roemen, G.M.J.M., Westra, A.H., Ossenkoppele, G.J., et al. (2003) "Multiparameter flow cytometric quantification of apoptosis-related protein expression", Leukemia, 17, 787-788.
41. Damle, R.N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S.L., et al. (1999) "Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia", Blood, 94, 1840-1847.
42. Kaufmann, S.H., Karp, J.E., Svingen, P.A., Krajewski, S., Burke, P.J., Gore, S.D., et al. (1998) "Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse", Blood, 91, 991-1000.
43. Zhan, Q., Bieszczad, C.K., Bae, I., Fornace, A.J. Jr. and Craig, R.W. (1996) "Induction of BCL2 family member MCL1 as an early response to DNA damage", Oncogene, 14, 1031-1039.
44. Jones, D.T., Ganeshaguru, K., Anderson, R.J., Jackson, T.R., Bruckdorfer, R., Low, S.Y., et al. (2003) "Albumin activates the AKT signaling pathway and protects B-chronic lymphocytic leukemia cells from chlorambucil- and radiation-induced apoptosis", Blood, 101, 3174-3180.
45. Wang, J.-M., Chao, J.-R., Chen, W., Kuo, M.-L., Yen, J.J. and Yang.-Yen, H.-F. (1999) "The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB", Molecular and Cellular Biology, 19, 6195-6206.
46. Bae, J., Donigian, J.R. and Hsueh, A.J.W. (2003) "Tankyrase 1 interacts with Mcl-1 proteins and inhibits their regulation of apoptosis", Journal of Biological Chemistry, 278, 5195-5204.
47. Zhang, B., Potyagaylo, V. and Fenton, R.G. (2003) "IL-6-independent expression of Mcl-1 in human multiple myeloma", Oncogene, 22, 1848-1859.
48. Khoury, J.D., Medeiros, L.J., Rassidakis, G.Z., McDonnell, T.J., Abruzzo, L.V. and Lai, R. (2003) "Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression", Journal of Pathology, 199, 90-97.
49. Krajewski, S., Bodrug, S., Gascoyne, R., Berean, K., Krajewska, M. and Reed, J.C. (1994) "Immunohistochemical analysis of mcl-1 and bcl-2 proteins in normal and neoplastic lymph nodes", American Journal of Pathology, 145, 515-525.
50. Henson, E.S., Gibson, E.M., Villanueva, J., Bristow, N.A. and Gibson, S.B. (2003) "Increased expression of Mcl-1 is responsible for the blockage of TRAIL-induced apoptosis mediated by EGF/ErbB1 signaling pathway", Journal of Cellular Biochemistry, 89, 1177-1192.
51. Begleiter, A., Mowat, M., Israels, L.G. and Johnston, J.B. (1996) "Chlorambucil in chronic lymphocytic leukemia - mechanism of action", Leukemia and Lymphoma, 23, 187-201.
52. Genini, D., Adachi, S., Chao, Q., Rose, C.J., Carrera, H.B., Cottam, D.A., et al. (2000) "Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria", Blood, 96, 3537-3543.
53. Pepper, C., Thomas, A., Hoy, T., Milligan, D., Bentley, P. and Fegan, C. (2003) "The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro", Blood, 101, 2454-2460.